LATEST LEUKEMIAS CONTENT

Duration of Response Contributes to Survival in COMMANDS Trial in MDS

Understanding the Role of Mutations in Staging of Low-Risk MDS

Targeted Therapy for BPDCN Provides Path to Allogeneic Transplant

Hoffmann Discusses Deciding Factors for Treating Patients With CLL

Investigating Beyond the First-Generation BTK Inhibitors in CLL

Managing Cardiac Toxicities with Zanubrutinib in Relapsed CLL

ALPINE Trial Data Shows Effectiveness of Zanubrutinib in Relapsed CLL
CASE-BASED ROUNDTABLES
Advertisement
Advertisement




